Kintara Therapeutics (KTRA) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy assigned a Buy rating to Kintara Therapeutics (KTRAResearch Report) yesterday and set a price target of $3.00. The company’s shares closed last Tuesday at $1.56.

According to, McCarthy is a 5-star analyst with an average return of 31.9% and a 50.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and Interpace Diagnostics Group.

Currently, the analyst consensus on Kintara Therapeutics is a Strong Buy with an average price target of $4.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.95 and a one-year low of $0.38. Currently, Kintara Therapeutics has an average volume of 457.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.